Non-BRCA1/BRCA2 high-risk familial breast cancers are not associated with a high prevalence of BRCAness

被引:1
|
作者
Andersen, Lars v. B. [1 ,2 ]
Larsen, Martin J. [1 ,2 ]
Davies, Helen [3 ,4 ]
Degasperi, Andrea [3 ,4 ]
Nielsen, Henriette Roed [5 ]
Jensen, Louise A. [1 ,2 ]
Kroeldrup, Lone [1 ]
Gerdes, Anne-Marie [6 ]
Laenkholm, Anne-Vibeke [7 ]
Kruse, Torben A. [1 ,2 ]
Nik-Zainal, Serena [3 ,4 ,5 ]
Thomassen, Mads [1 ,2 ]
机构
[1] Odense Univ Hosp, Dept Clin Genet, Odense, Denmark
[2] Univ Southern Denmark, Clin Genome Ctr, Dept Clin Res, Odense, Denmark
[3] Univ Cambridge, Early Canc Inst, Hutchison Res Ctr, Cambridge Biomed Campus, Cambridge CB2 0XZ, England
[4] Addenbrookes Hosp, Addenbrookes Treatment Ctr Lv 6, Acad Lab Med Genet, Cambridge CB2 0QQ, England
[5] European Sperm Bank, Copenhagen, Denmark
[6] Copenhagen Univ Hosp Rigshospitalet, Dept Clin Genet, Copenhagen, Denmark
[7] Zealand Univ Hosp, Dept Surg Pathol, DK-4000 Roskilde, Denmark
关键词
Breast cancer; Hereditary breast cancer; Non-BRCA1; BRCA2; Whole genome sequencing; Mutational signatures; HRDetect; BRCAness; TUMOR MUTATIONAL BURDEN; BRCA2; MUTATIONS; DEFICIENCY; SIGNATURES; PREDICTOR; LANDSCAPE; GENES; TOOL;
D O I
10.1186/s13058-023-01655-y
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundFamilial breast cancer is in most cases unexplained due to the lack of identifiable pathogenic variants in the BRCA1 and BRCA2 genes. The somatic mutational landscape and in particular the extent of BRCA-like tumour features (BRCAness) in these familial breast cancers where germline BRCA1 or BRCA2 mutations have not been identified is to a large extent unknown.MethodsWe performed whole-genome sequencing on matched tumour and normal samples from high-risk non-BRCA1/BRCA2 breast cancer families to understand the germline and somatic mutational landscape and mutational signatures. We measured BRCAness using HRDetect. As a comparator, we also analysed samples from BRCA1 and BRCA2 germline mutation carriers.ResultsWe noted for non-BRCA1/BRCA2 tumours, only a small proportion displayed high HRDetect scores and were characterized by concomitant promoter hypermethylation or in one case a RAD51D splice variant previously reported as having unknown significance to potentially explain their BRCAness. Another small proportion showed no features of BRCAness but had mutationally active tumours. The remaining tumours lacked features of BRCAness and were mutationally quiescent.ConclusionsA limited fraction of high-risk familial non-BRCA1/BRCA2 breast cancer patients is expected to benefit from treatment strategies against homologue repair deficient cancer cells.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] Analysis of polymorphisms in genes encoding proteins interacting with BRCA1 in high-risk non-BRCA1/2 families
    Guenard, F
    Labrie, Y
    Ouellette, G
    Houde, M
    Simard, J
    Durocher, F
    AMERICAN JOURNAL OF HUMAN GENETICS, 2003, 73 (05) : 231 - 231
  • [22] Non-BRCA1/2 Variants Detected in a High-Risk Chilean Cohort With a History of Breast and/or Ovarian Cancer
    Adaniel, Christina
    Salinas, Francisca
    Manuel Donaire, Juan
    Eugenia Bravo, Maria
    Peralta, Octavio
    Paredes, Hernando
    Aliaga, Nuvia
    Sola, Antonio
    Neira, Pauline
    Behnke, Carolina
    Rodriguez, Tulio
    Torres, Soledad
    Lopez, Francisco
    Hurtado, Claudia
    JOURNAL OF GLOBAL ONCOLOGY, 2019, 5 : 1 - 14
  • [23] Prevalence of Germline BRCA1 and BRCA2 Deleterious Mutations in Brazilian Patients with High-Risk of Breast and Ovarian Cancer.
    Diz, M. D. P. E.
    Escobar, K. A.
    Guindalini, R. S. C.
    Pasini, F. S.
    Snitkoyiski, M. L.
    Maistro, S.
    Hoff, P. M. G.
    Federico, M. H. H.
    CANCER RESEARCH, 2011, 71
  • [24] Prevalence of high-risk lesions in prophylactic mastectomy specimens of 82 BRCA1 and BRCA2 mutation carriers
    Hoogerbrugge, N.
    Bult, P.
    Ligtenberg, M. J. L.
    Bonenkamp, J. J.
    de Hullu, J. A.
    Niermeijer, M. F.
    Brunner, H. G.
    EJC SUPPLEMENTS, 2005, 3 (02): : 65 - 65
  • [25] A predictor based on the somatic genomic changes of the BRCA1/BRCA2 breast cancer tumors identifies the non-BRCA1/BRCA2 tumors with BRCA1 promoter hypermethylation
    Alvarez, S
    Diaz-Uriarte, R
    Osorio, A
    Barroso, A
    Melchor, L
    Paz, MF
    Honrado, E
    Rodríguez, R
    Urioste, M
    Valle, L
    Díez, O
    Cigudosa, JC
    Dopazo, J
    Esteller, M
    Benitez, J
    CLINICAL CANCER RESEARCH, 2005, 11 (03) : 1146 - 1153
  • [26] Prevalence of the variant allele rs61764370 T>G in the 3′UTR of KRAS among Dutch BRCA1, BRCA2 and non-BRCA1/BRCA2 breast cancer families
    Antoinette Hollestelle
    Cory Pelletier
    Maartje Hooning
    Ellen Crepin
    Mieke Schutte
    Maxime Look
    J. Margriet Collee
    Anja Nieuwlaat
    Lambert C. J. Dorssers
    Caroline Seynaeve
    Yurii S. Aulchenko
    John W. M. Martens
    Ans M. W. van den Ouweland
    Joanne B. Weidhaas
    Breast Cancer Research and Treatment, 2011, 128 : 79 - 84
  • [27] Large BRCA1 and BRCA2 genomic rearrangements in Polish high-risk breast and ovarian cancer families
    Rudnicka, Helena
    Debniak, Tadeusz
    Cybulski, Cezary
    Huzarski, Tomasz
    Gronwald, Jacek
    Lubinski, Jan
    Gorski, Bohdan
    MOLECULAR BIOLOGY REPORTS, 2013, 40 (12) : 6619 - 6623
  • [28] Large BRCA1 and BRCA2 genomic rearrangements in Polish high-risk breast and ovarian cancer families
    Helena Rudnicka
    Tadeusz Debniak
    Cezary Cybulski
    Tomasz Huzarski
    Jacek Gronwald
    Jan Lubinski
    Bohdan Gorski
    Molecular Biology Reports, 2013, 40 : 6619 - 6623
  • [29] Assessment of individuals with BRCA1 and BRCA2 large rearrangements in high-risk breast and ovarian cancer families
    Arnold, Angela G.
    Otegbeye, Ebunoluwa
    Fleischut, Megan Harlan
    Glogowski, Emily A.
    Siegel, Beth
    Boyar, Sherry R.
    Salo-Mullen, Erin
    Amoroso, Kim
    Sheehan, Margaret
    Berliner, Janice L.
    Stadler, Zsofia K.
    Kauff, Noah D.
    Offit, Kenneth
    Robson, Mark E.
    Zhang, Liying
    BREAST CANCER RESEARCH AND TREATMENT, 2014, 145 (03) : 625 - 634
  • [30] Transcriptome mining of non-BRCA1/A2 and BRCA1/A2 familial breast cancer
    Akbari, Vahid
    Kallhor, Marzieh
    Akbari, Mohammad Taghi
    JOURNAL OF CELLULAR BIOCHEMISTRY, 2019, 120 (01) : 575 - 583